Our first major joint project with REN-HUN BRC aims to develop bacteriophage-based commercial products to treat multi-resistant bacterial infections, an increasingly severe problem in world-wide healthcare. Our scientists bring together highly innovative approaches and information from molecular epidemiology, molecular biology and microbiology and are putting these together to provide market-disruptive treatments for patients in Europe and beyond.
We are rapidly advancing these technologies towards early clinical applications and preparing for wide-spread use in the coming years.
If you are interested to hear more or to become part of our journey, get in touch!